Silo Pharma Posts Encouraging Preclinical Data For Alzheimer's Candidate

Silo Pharma Inc SILO has announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease (AD).
The research was conducted as part of a sponsored research agreement with Columbia University in New York.
Silo Pharma's Commercial Evaluation License Agreement (CELA) with Columbia University grants an option to license two investigational assets - SPC-14 targeting Alzheimer's disease and SPC-15 targeting stress-induced affective disorders.
SPC-14 combines an FDA-approved therapeutic with ketamine. It is in development for dementia related to Alzheimer's disease.
Initial data from its SPC-14 research studies show that chronic dosing of SPC-14 resulted in increased memory in AD mice and had no negative weight effects on the subjects.
"The result from these studies is a first step in the development of SPC-14 as a potential therapeutic for the treatment of Alzheimer's," said Eric Weisblum, Chief Executive Officer of Silo Pharma...We believe SPC-14 should be eligible for development under the FDA's 505(b)(2) regulatory pathway. This will allow Silo Pharma to reach efficacy clinical trials faster and save costs."
Earlier this week, Columbia University granted Silo an extension for its option to license certain assets currently under development, including Alzheimer's disease and Stress-Induced Anxiety.
Price Action: SILO shares closed at $4.78 on Wednesday.